



Universiteit  
Leiden  
The Netherlands

## Immune checkpoint inhibitors in mesothelioma

Disselhorst, M.J.

### Citation

Disselhorst, M. J. (2022, October 25). *Immune checkpoint inhibitors in mesothelioma*. Retrieved from <https://hdl.handle.net/1887/3483978>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3483978>

**Note:** To cite this publication please use the final published version (if applicable).

# Immune checkpoint inhibitors in mesothelioma

Maria J. Disselhorst

Colofon

ISBN: **xxxxxxxx**

Design cover: Erica Cardenas || <https://ericacardenas.com/>

Printed by: ProefschriftMaken || [www.proefschriftmaken.nl](http://www.proefschriftmaken.nl)

# Immune checkpoint inhibitors in mesothelioma

Proefschrift

ter verkrijging van  
de graad van doctor aan de Universiteit Leiden,  
op gezag van rector magnificus prof.dr.ir. H. Bijl,  
volgens besluit van het college voor promoties  
te verdedigen op dinsdag 25 oktober 2022  
klokke 11.15 uur

door  
Maria Johanna Disselhorst  
geboren te Castricum  
in 1981

Promotor

Prof. Dr. P. Baas, Antoni van Leeuwenhoek – Nederlands Kanker Instituut

Copromotor

Dr. J.A. Burgers, Antoni van Leeuwenhoek- Nederlands Kanker Instituut

Leden promotiecommissie

Prof. Dr. J.J.C Neefjes

Prof. Dr. J.G. Borst

Prof. Dr. P.S. Hiemstra

Prof. Dr. J. van Meerbeeck, Universitair Ziekenhuis Antwerpen, België

Prof. A. Mansfield, Mayo Clinic, Rochester, Minnesota, USA

# Table of contents

|                                                                                                                                                                                                               |     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Chapter 1 General introduction and outline of thesis                                                                                                                                                          | 7   |
| <b>PART I Mesothelioma treatment</b>                                                                                                                                                                          | 27  |
| Chapter 2 Optimal therapy of advanced stage mesothelioma                                                                                                                                                      | 29  |
| Chapter 3 Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma.                                                                                    | 41  |
| Chapter 4 ESMO handbook of Immuno-Oncology – chapter Mesothelioma                                                                                                                                             | 57  |
| <b>PART II Clinical research</b>                                                                                                                                                                              | 67  |
| Chapter 5 Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial                                               | 69  |
| <b>PART III Translational research</b>                                                                                                                                                                        | 99  |
| Chapter 6 Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: translational evidence from two clinical trials. | 101 |
| Chapter 7 eNose in malignant mesothelioma – prediction of response to immune checkpoint inhibitor treatment                                                                                                   | 123 |
| Chapter 8 Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?                                                                                           | 141 |
| Chapter 9 Tumor junction burden and antigen presentation as predictors of survival in mesothelioma treated with immune checkpoint inhibitors                                                                  | 157 |
| <b>Part IV</b>                                                                                                                                                                                                | 187 |
| Chapter 10 Discussion                                                                                                                                                                                         | 189 |
| Chapter 11 Summary                                                                                                                                                                                            | 201 |
| Chapter 12 Nederlandse samenvatting                                                                                                                                                                           | 209 |
| List of publications                                                                                                                                                                                          | 216 |
| Curriculum vitae                                                                                                                                                                                              | 218 |